Preclinical data demonstrates IMR-687 reduces white cell pathologies associated with the disease Phase 1 clinical study demonstrates once-daily, oral dosing IMR-687 is safe and well-tolerated at ...

** When you buy products through the links on our site, we may earn a commission that supports NRA's mission to protect, preserve and defend the Second Amendment. ** Now what do I do? Poke an eye out ...

Company encouraged by interim 13-week data in trial designed to assess the safety and tolerability of IMR-687 and explore the potential efficacy of IMR-687 on clinical outcome measures relevant to ...

BOSTON, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients ...

Arix Bioscience plc (LSE: ARIX) ("Arix"), a global venture capital company focused on investing and building breakthrough biotech companies, notes that its portfolio company Imara, Inc. ("Imara") has ...